Tarceva (erlotinib), a new ORAL treatment for non-small cell lung cancer (NSCLC)

January 2005

You'll soon see patients on Tarceva (erlotinib), a new ORAL treatment for non-small cell lung cancer (NSCLC).

It's related to gefitinib (Iressa). These two drugs are intended to target growth factors that stimulate tumor growth.

The difference is that Tarceva extends life two months longer than placebo. Iressa is unable to show any improved survival.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote